全文获取类型
收费全文 | 222篇 |
免费 | 11篇 |
专业分类
儿科学 | 9篇 |
妇产科学 | 2篇 |
基础医学 | 31篇 |
口腔科学 | 4篇 |
临床医学 | 10篇 |
内科学 | 67篇 |
皮肤病学 | 1篇 |
神经病学 | 23篇 |
特种医学 | 8篇 |
外科学 | 39篇 |
综合类 | 2篇 |
预防医学 | 11篇 |
眼科学 | 4篇 |
药学 | 14篇 |
中国医学 | 2篇 |
肿瘤学 | 6篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 8篇 |
2013年 | 11篇 |
2012年 | 10篇 |
2011年 | 11篇 |
2010年 | 8篇 |
2009年 | 10篇 |
2008年 | 7篇 |
2007年 | 15篇 |
2006年 | 18篇 |
2005年 | 9篇 |
2004年 | 9篇 |
2003年 | 9篇 |
2002年 | 9篇 |
2001年 | 14篇 |
2000年 | 4篇 |
1999年 | 9篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 5篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1973年 | 2篇 |
1970年 | 4篇 |
1968年 | 1篇 |
1967年 | 3篇 |
1966年 | 1篇 |
1957年 | 1篇 |
1907年 | 1篇 |
排序方式: 共有233条查询结果,搜索用时 15 毫秒
101.
Autologous hematopoietic stem cell transplantation (HSCT) has been used for the treatment of both adult and pediatric autoimmune
diseases. However, HSCT has significant side effects (neutropenia, thrombocytopenia, infertility, cardiotoxicity) and costs
(HSC collection/harvesting, blood product support). In an attempt to avoid the toxicities and costs associated with HSCT,
we investigated whether immune ablation similar to that achieved following myeloablative HSCT could be achieved by the intensive
administration of an anti-CD52 antibody (Campath-1H antibody). The first patient treated with the treatment regime, who had
refractory juvenile polymyositis, achieved immune ablation (the elimination of pre-therapy antigen-specific T lymphocyte immunity)
and has had stable clinical improvement for more than 6 years. 相似文献
102.
Subcommittee on Attention-Deficit/Hyperactivity Disorder;Steering Committee on Quality Improvement Management Wolraich M Brown L Brown RT DuPaul G Earls M Feldman HM Ganiats TG Kaplanek B Meyer B Perrin J Pierce K Reiff M Stein MT Visser S 《Pediatrics》2011,128(5):1007-1022
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood and can profoundly affect the academic achievement, well-being, and social interactions of children; the American Academy of Pediatrics first published clinical recommendations for the diagnosis and evaluation of ADHD in children in 2000; recommendations for treatment followed in 2001. 相似文献
103.
Ferraresi C de Brito Oliveira T de Oliveira Zafalon L de Menezes Reiff RB Baldissera V de Andrade Perez SE Matheucci Júnior E Parizotto NA 《Lasers in medical science》2011,26(3):349-358
Recent studies have investigated whether low level laser therapy (LLLT) can optimize human muscle performance in physical
exercise. This study tested the effect of LLLT on muscle performance in physical strength training in humans compared with
strength training only. The study involved 36 men (20.8±2.2 years old), clinically healthy, with a beginner and/or moderate
physical activity training pattern. The subjects were randomly distributed into three groups: TLG (training with LLLT), TG
(training only) and CG (control). The training for TG and TLG subjects involved the leg-press exercise with a load equal to
80% of one repetition maximum (1RM) in the leg-press test over 12 consecutive weeks. The LLLT was applied to the quadriceps
muscle of both lower limbs of the TLG subjects immediately after the end of each training session. Using an infrared laser
device (808 nm) with six diodes of 60 mW each a total energy of 50.4 J of LLLT was administered over 140 s. Muscle strength
was assessed using the 1RM leg-press test and the isokinetic dynamometer test. The muscle volume of the thigh of the dominant
limb was assessed by thigh perimetry. The TLG subjects showed an increase of 55% in the 1RM leg-press test, which was significantly
higher than the increases in the TG subjects (26%, P = 0.033) and in the CG subjects (0.27%, P < 0.001). The TLG was the only group to show an increase in muscle performance in the isokinetic dynamometry test compared
with baseline. The increases in thigh perimeter in the TLG subjects and TG subjects were not significantly different (4.52%
and 2.75%, respectively; P = 0.775). Strength training associated with LLLT can increase muscle performance compared with strength training only. 相似文献
104.
BACKGROUND: Although serum thyroglobulin (Tg) is an excellent marker for detecting recurrent or persistent differentiated thyroid cancer (DTC), it is unreliable in patients who have positive anti-Tg antibodies. Furthermore, a growing number of patients with DTC have elevated Tg levels but no detectable disease on radioiodine scanning or other imaging studies. The objective of this study was to determine whether a gradient in Tg protein level exists in patients with DTC. METHODS: Fifteen patients who underwent thyroidectomy and/or lymph node dissection for primary DTC (n = 10 patients) and recurrent or persistent DTC (n = 5 patients). A venipuncture was performed simultaneously from the internal jugular vein adjacent to the tumor and the ipsilateral antecubital vein. Venous Tg protein levels were measured by using a chemiluminescence assay. RESULTS.: The average internal jugular-to-antecubital vein Tg protein ratio was 3.4:1.0 (median Tg ratio, 2.9:1; range, 0.8-62.2). Four patients had positive anti-Tg antibodies but still had a Tg gradient. Tg levels were significantly higher in the adjacent internal jugular vein than in the antecubital vein (P = .0019). The Tg ratio between the internal jugular and antecubital veins was significantly higher in patients with recurrent or persistent DTC than in patients with primary tumors (P = .0196). CONCLUSIONS: To the authors' knowledge, this is the first study to document a venous gradient in Tg protein levels in patients with DTC. The findings suggested that venous sampling for Tg may be used to localize DTC in some patients who have high or increasing serum Tg levels but negative radioiodine scans or imaging studies. 相似文献
105.
BACKGROUND: Radioactive iodine (RAI) treatment has been suggested to cause primary hyperparathyroidism (HPT). We describe a series of patients with HPT and a history of RAI exposure. METHODS: Patient demographic and clinical information was evaluated, including the latency time to the development of HPT after RAI exposure. RESULTS: We treated 11 patients with HPT and a history of RAI exposure. RAI treatment was administered for benign thyroid disease in 9 (82%) cases. Thirty-six cases of HPT after RAI exposure in the English literature were compiled for further analysis. In this collective experience, the average latency time to the development of HPT after RAI treatment was 13.5 +/- 9.1 years and was found to be inversely correlated with age at RAI exposure. CONCLUSIONS: Patients who undergo RAI treatment are at risk of developing HPT, and this risk appears to increase in elderly patients. Serum calcium surveillance is recommended for patients who have undergone RAI treatment. 相似文献
106.
Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study 总被引:1,自引:0,他引:1
Witt K Daniels C Reiff J Krack P Volkmann J Pinsker MO Krause M Tronnier V Kloss M Schnitzler A Wojtecki L Bötzel K Danek A Hilker R Sturm V Kupsch A Karner E Deuschl G 《Lancet neurology》2008,7(7):605-614
BACKGROUND: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) reduces motor symptoms in patients with Parkinson's disease (PD) and improves their quality of life; however, the effect of DBS on cognitive functions and its psychiatric side-effects are still controversial. To assess the neuropsychiatric consequences of DBS in patients with PD we did an ancillary protocol as part of a randomised study that compared DBS with the best medical treatment. METHODS: 156 patients with advanced Parkinson's disease and motor fluctuations were randomly assigned to have DBS of the STN or the best medical treatment for PD according to the German Society of Neurology guidelines. 123 patients had neuropsychological and psychiatric examinations to assess the changes between baseline and after 6 months. The primary outcome was the comparison of the effect of DBS with the best medical treatment on overall cognitive functioning (Mattis dementia rating scale). Secondary outcomes were the effects on executive function, depression, anxiety, psychiatric status, manic symptoms, and quality of life. Analysis was per protocol. The study is registered at ClinicalTrials.gov, number NCT00196911. FINDINGS: 60 patients were randomly assigned to receive STN-DBS and 63 patients to have best medical treatment. After 6 months, impairments were seen in executive function (difference of changes [DBS-best medical treatment] in verbal fluency [semantic] -4.50 points, 95% CI -8.07 to -0.93, Cohen's d=-;0.4; verbal fluency [phonemic] -3.06 points, -5.50 to -0.62, -0.5; Stroop 2 naming colour error rate -0.37 points, -0.73 to 0.00, -0.4; Stroop 3 word reading time -5.17 s, -8.82 to -1.52, -0.5; Stroop 4 colour naming time -13.00 s, -25.12 to -0.89, -0.4), irrespective of the improvement in quality of life (difference of changes in PDQ-39 10.16 points, 5.45 to 14.87, 0.6; SF-36 physical 16.55 points, 10.89 to 22.21, 0.9; SF-36 psychological 9.74 points, 2.18 to 17.29, 0.5). Anxiety was reduced in the DBS group compared with the medication group (difference of changes in Beck anxiety inventory 10.43 points, 6.08 to 14.78, 0.8). Ten patients in the DBS group and eight patients in the best medical treatment group had severe psychiatric adverse events. INTERPRETATION: DBS of the STN does not reduce overall cognition or affectivity, although there is a selective decrease in frontal cognitive functions and an improvement in anxiety in patients after the treatment. These changes do not affect improvements in quality of life. DBS of the STN is safe with respect to neuropsychological and psychiatric effects in carefully selected patients during a 6-month follow-up period. FUNDING: German Federal Ministry of Education and Research (01GI0201). 相似文献
107.
Reiff A Lovell DJ Adelsberg JV Kiss MH Goodman S Zavaler MF Chen PY Bolognese JA Cavanaugh P Reicin AS Giannini EH 《The Journal of rheumatology》2006,33(5):985-995
OBJECTIVE: To compare the safety and efficacy of rofecoxib* to naproxen for the treatment of juvenile rheumatoid arthritis (JRA). METHODS: This was a 12-week, multicenter, randomized, double-blind, double-dummy, active comparator-controlled, non-inferiority study with a prespecified 52-week open-label active comparator-controlled extension. Children (ages 2-11 yrs) and adolescents (ages 12-17 yrs) received lower-dose (LD)-rofecoxib [0.3 mg/kg/day up to 12.5 mg/day (base study only)]; or higher-dose (HD)-rofecoxib (0.6 mg/kg/day up to 25 mg/day) or naproxen 15 mg/kg/day as oral suspensions. Adolescents received daily rofecoxib (LD) 12.5 (base study only) or (HD) 25 mg, or naproxen 15 mg/kg/day (maximum 1,000 mg/day) as tablets. The primary endpoint was the time-weighted average proportion of patients meeting the American College of Rheumatology Pediatric-30 (ACR Pedi 30) response criteria. A prespecified bound for the 95% confidence interval for the ratio of the percentage of ACR Pedi 30 responders was used to assess non-inferiority of treatment response between groups. Safety was assessed throughout the study. RESULTS: A total of 310 patients ages 2-17 years (181 (3/4) age 11) were randomized to receive LD-rofecoxib (N=109), HD-rofecoxib (N=100), or naproxen (N=101). The ACR Pedi 30 response rates following 12 weeks of treatment were 46.2%, 54.5%, and 55.1%, respectively. The relative rates of response compared to naproxen were 0.81 (95% CI 0.61, 1.07) and 0.98 (95% CI 0.76, 1.26) for LD- and HD-rofecoxib, respectively. Both rofecoxib doses were not inferior to naproxen. Patients (N=227) entering the extension received HD-rofecoxib or naproxen with efficacy maintained during the extension. All treatments were generally well tolerated throughout the study. CONCLUSION: Daily treatment of JRA patients with rofecoxib up to 12.5 or 25 mg was well tolerated, providing sustained clinical effectiveness comparable to naproxen 15 mg/kg. *On September 30, 2004, Merck & Co., Inc. announced the voluntary worldwide withdrawal of rofecoxib from the market. 相似文献
108.
Reiff A 《Current rheumatology reports》2006,8(6):459-468
Ocular involvement is common in pediatric rheumatologic diseases, supporting the concept that these conditions cannot be understood
simply as isolated entities, but rather as multisystem disorders. The reasons for the breach of the eye-brain barrier and
the targeting of the usually well-shielded eye during a pan-inflammatory process remains unclear. Pediatric rheumatologists
should become familiar with these ocular disorders, because as important members of the treatment team, they manage more serious
cases of inflammatory eye disease. A close collaboration between the treating rheumatologist and the ophthalmologist is essential
to prevent potentially devastating outcomes. Therapeutic interventions such as topical steroids, systemic immunosuppressants,
and biologics must balance the necessity of controlling ocular inflammation and the adverse effects of these treatments on
a growing child. 相似文献
109.
Dr. Robert Reiff Ph.D. 《Community mental health journal》1966,2(3):193-196
Social and psychological issues that may arise for those who will be working in a future cybernated society are discussed. An analysis of the psychological concomitants of the changes cybernation will effect in man's relationship with this work is attempted. Social sexual concomitants of shifting large sections of present day workers into human service occupations which are generally considered feminine are also considered. What is needed is a grand strategy of social change, a national plan involving every aspect of society which will take advantage of cybernation to construct a society without labor but which at the same time does not threaten present day laborers with exclusion from society. 相似文献
110.
Ruperto N Buratti S Duarte-Salazar C Pistorio A Reiff A Bernstein B Maldonado-Velázquez MR Beristain-Manterola R Maeno N Takei S Falcini F Lepore L Spencer CH Pratsidou-Gertsi P Martini A Ravelli A 《Arthritis and rheumatism》2004,51(3):458-464
OBJECTIVE: To assess the health-related quality of life (HRQL) of patients with juvenile-onset systemic lupus erythematosus (JSLE) and its relationship with disease activity and accumulated damage. METHODS: In this cross-sectional study, HRQL was assessed using the Child Health Questionnaire (CHQ), disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and accumulated damage using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). RESULTS: A total of 297 patients were included. The mean +/- SD physical and psychosocial summary scores of the CHQ were 40.2 +/- 15.0 and 44.8 +/- 10.7, respectively. The most impaired CHQ subscales were global health, general health perceptions, and parent impact-emotional. The SLEDAI score was significantly correlated with both the physical summary score (r = -0.29, P < 0.0001) and psychosocial summary score (r = -0.25, P < 0.0001), whereas the SDI score was significantly correlated only with the physical summary score (r = -0.23, P = 0.0001). CONCLUSION: We found that patients with JSLE have significant impairment of their HRQL, particularly in the physical domain. HRQL may be affected by both disease activity and accumulated damage, particularly in the renal, central nervous, and musculoskeletal systems. 相似文献